Conference Coverage

High efficacy, no safety signals for herpes zoster vaccine post-HSCT

Publish date: March 7, 2018

 

REPORTING FROM THE 2018 BMT TANDEM MEETINGS

SOURCE: de la Serna J et al. 2018 BMT Tandem Meetings, Abstract LBA2.

Pages

Recommended Reading

FIRST trial analysis shows more benefit for lenalidomide
MDedge Hematology and Oncology
Cutaneous multiple myeloma is a deadly indicator
MDedge Hematology and Oncology
Denosumab on par with zoledronic acid for multiple myeloma bone disease
MDedge Hematology and Oncology
Export protein inhibitor shows activity against refractory myeloma
MDedge Hematology and Oncology
Drug approved to treat newly diagnosed MM in China
MDedge Hematology and Oncology
CHMP supports approval of denosumab in MM
MDedge Hematology and Oncology
Regimen deemed ‘safe and feasible’ in MM
MDedge Hematology and Oncology
Study reveals lack of sexual aids for cancer survivors
MDedge Hematology and Oncology
Drug receives orphan designation for MM
MDedge Hematology and Oncology
Agent can decrease GI toxicity in MM patients
MDedge Hematology and Oncology